Cholecystokinin in anxiety

Abelson, 1990, Cholecystokinin-4 and panic, Arch. Gen. Psychiatry, 47, 395, 10.1001/archpsyc.1990.01810160095016 Abelson, 1994, Pentagastrin infusion in patients with panic disorder. I. Symptoms and cardiovascular responses, Biol. Psychiatry, 36, 73, 10.1016/0006-3223(94)91187-8 Albus, 1992, Anxiogenic effects of yohimbine. I. Behavioral, physiological and biochemical measures, Eur. Arch. Psychiatry, 241, 337, 10.1007/BF02191958 American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Beinfeld, 1981, Distribution of cholecystokinin in the hippothalamus and the limbic system of the rat, Neuropeptides, 2, 123, 10.1016/0143-4179(81)90061-5 Belzung, 1994, PD135158, a CCK-B Antagonist, reduces ‘state’, but not ‘trait’ anxiety in mice, Pharmacol. Biochem. Behav., 49, 433, 10.1016/0091-3057(94)90445-6 Bickerdike, 1994, CCK antagonist effects in the rat elevated zero-maze model of anxiety: influence of 5-HT re-uptake blockade, Eur. J. Pharmacol., 271, 403, 10.1016/0014-2999(94)90800-1 Black, 1993, A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder, Arch. Gen. Psychiatry, 50, 44, 10.1001/archpsyc.1993.01820130046008 Blanke, 1993, N-terminal fragments of intestinal cholecystokinin - evidence for release of CCK-8 by cleavage on the carboxyl side arg(74) of proCCK, Regul. Peptides, 46, 575, 10.1016/0167-0115(93)90259-B Boden, 1991, Pharmacology of a chlolecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain, Br. J. Pharmacol., 102, 635, 10.1111/j.1476-5381.1991.tb12225.x Böhme, 1988, Excitatory effects of cholecystokinin in rat hippocampus: pharmacological response compatible with ‘central’ or B-type CCK receptors, Brain Res., 451, 309, 10.1016/0006-8993(88)90776-7 Bouthillier, 1988, Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat, Eur. J. Pharmacol., 151, 135, 10.1016/0014-2999(88)90703-0 Bradwejn, 1984, Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones, Nature, 312, 363, 10.1038/312363a0 Bradwejn, 1985, Antagonism of cholecystokinin-induced activation by benzodiazepine receptor agonists, Ann. NY Acad. Sci., 448, 575, 10.1111/j.1749-6632.1985.tb29954.x Bradwejn, 1985, Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat, Eur. J. Pharmacol., 112, 415, 10.1016/0014-2999(85)90790-3 Bradwejn, 1991, Comparison of the panicogenic effect of cholecystokinin 30–33 and carbon dioxide in panic disorder, Prog. Neuropsychopharmacol. Biol. Psychiatry, 15, 237, 10.1016/0278-5846(91)90086-G Bradwejn, 1994, Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients, Am. J. Psychiatry, 151, 261, 10.1176/ajp.151.2.261 Bradwejn, 1990, Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder, Can. J. Psychiatry, 35, 83, 10.1177/070674379003500115 Bradwejn, 1991, Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder, Arch. Gen. Psychiatry, 48, 603, 10.1001/archpsyc.1991.01810310021005 Bradwejn, 1991, Dose ranging study of the effects of cholecystokinin in healthy volunteers, J. Psychiatr. Neurosci., 16, 91 Bradwejn, 1992, Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings, Am. J. Psychiatry, 149, 962, 10.1176/ajp.149.7.962 Bradwejn, 1992, A dose-ranging study of the behavioural and cardiovascular effcts of CCK-tetrapeptide in panic disorder, Biol. Psychiatry, 32, 903, 10.1016/0006-3223(92)90179-4 Bradwejn, 1992, The cholecystokinin hypothesis of panic anxiety disorders: a review, J. Psychopharmacol., 6, 351, 10.1177/026988119200600301 Bradwejn, 1994, The panicogenic effects of cholecystokinin tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist in patients with panic disorder, Arch. Gen. Psychiatry, 51, 486, 10.1001/archpsyc.1994.03950060050005 Bradwejn, 1994, The effects of CI-988 on CCK-4 panic in heathy volunteers, Neuropsychopharmacology, 10, O-27 Bradwejn, 1994, Effects of flumazenil on cholecystokinin-tetra-peptide-induced panic symptoms in healthy volunteers, Psychopharmacology, 114, 257, 10.1007/BF02244846 Branchereau, 1992, CCK modulates inhibitory synaptic transmission in the solitary complex through CCKR sites, Neuroreport, 3, 909, 10.1097/00001756-199210000-00022 Brooks, 1985, Cholecystokinin as a potent excitant of neurons of the dentate gyrus in rats, Ann. NY Acad. Sci., 448, 123, 10.1111/j.1749-6632.1985.tb29931.x Chang, 1986, Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist, 83, 2926 Charney, 1992, Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder, Acta Psychiatr. Scand., 86, 273, 10.1111/j.1600-0447.1992.tb03266.x Chamey, 1994, The role of noradrenergic functioning in human anxiety and depression, 473 Charrier, 1995, failure of CCK receptor ligands to modify anxiety-related behavioral suppression in an operant conflict paradigm in rats, Psychopharmacology, 121, 127, 10.1007/BF02245599 Chopin, 1993, The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze, Psychopharmacology, 110, 409, 10.1007/BF02244646 Cohen, 1983, Tolerance to the anti-avoidance properties of cholecystokinin-octapeptide, Peptides, 4, 67, 10.1016/0196-9781(83)90168-7 Costall, 1991, Anxiolytic effects of CCK-B antagonists, Neuropeptides, 19, 65, 10.1016/0143-4179(91)90084-V Cowley, 1991, Lactate vulnerability after alprazolan versus placebo treatment of panic disorder, Biol. Psychiatry, 30, 49, 10.1016/0006-3223(91)90069-X Crawley, 1985, Neurochemical Investigation of the afferent pathway from the vagus nerve to the nucleus tractus solitarius in mediating the ‘satiety syndrome’ induced by systemic cholecystokinin, Peptides, 6, 133, 10.1016/0196-9781(85)90022-1 Cross, 1988, Characteristics of 123I-Bolton Hunter labelled cholecystokinin binding in human brain, Neuropeptides, 11, 73, 10.1016/0143-4179(88)90013-3 Csonka, 1988, Anxiogenic effect of cholecystokinin in rats, Peptides, 249 Cutler, 1994, Pilot study of a CCK-B antagonist in panic disorder Dahl, 1987, Systemically administered cholescystokinin affects an evoked potential in the hippocampus dentate gyrus, Neuropeptides, 10, 165, 10.1016/0143-4179(87)90018-7 Dahl, 1978, The action of cholecystokinin in the dentate gyrus. Stimulation of the locus coeruleus, Exp. Brain Res., 59, 491 Dawson, 1995, Lack of effect of CCK-B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs, Psychopharmacology, 121, 109, 10.1007/BF02245597 De Leeuw, 1996, Pentagastrin has panic-inducing properties in obsessive compulsive disorder, Psychopharmacology, 126, 339, 10.1007/BF02247385 De Montigny, 1989, Cholecystokinin tetrapeptide induces panic like attacks in healthy volunteers, Arch. Gen. Psychiatry, 46, 511, 10.1001/archpsyc.1989.01810060031006 De Weerth, 1993, Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor, Biochem. Biophys. Res. Commun., 2, 811, 10.1006/bbrc.1993.1894 De la Mora, 1993, Cholecystokinin-8 increases K+-evoked [3H] γ-aminobutyric acid release in slices from rat brain areas, Eur. J. Pharmacol., 250, 423, 10.1016/0014-2999(93)90029-H Den Boer, 1988, Effect of a serotonin and noradrenaline uptake inhibitor in panic disorders; a double blind study with fluvoxamine and maprotiline, Int. Clin. Psychopharmacol., 3, 59, 10.1097/00004850-198801000-00005 Den Boer, 1990, Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin, Psychopharmacology, 102, 85, 10.1007/BF02245749 Den Boer, 1987, Effect of serotonin uptake inhibitors in anxiety disorders, a double-blind comparison of clomipramine and fluvoxamine, Int. Clin. Psychopharmacol., 2, 21, 10.1097/00004850-198701000-00002 Denavit-Soubie, 1985, The effect of cholecystokinin-8 on the nucleus tractus solitarius, Ann. NY Acad. Sci., 448, 375, 10.1111/j.1749-6632.1985.tb29932.x Derrien, 1994, Heterogeneity of CCK-B receptors involved in animal models of anxiety, Pharmacol. Biochem. Behav., 49, 133, 10.1016/0091-3057(94)90467-7 Deschenes, 1984, Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin, 81, 726 Deschodt-Lanckman, 1981, Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. I. Evidence for competition with enkephalins for in vitro common degradation pathways, Peptides, 2, 113, 10.1016/0196-9781(81)90021-8 Deschodt-Lanckman, 1984, Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. III. Inactivation of CCK-8 by a phosphoramidonsensitive endopeptidase, Peptides, 5, 649, 10.1016/0196-9781(84)90098-6 Dethloff, 1992, Cholecystokinin antagonists - a toxicologic perspective, Drug Metab. Rev., 24, 267, 10.3109/03602539208996295 Dietl, 1987, On the distribution of cholecystokinin receptor binding sites in the human brain: an autoradiographic study, Synapse, 1, 169, 10.1002/syn.890010205 Dockray, 1976, Immunochemical evidence of cholecystokinin-like peptides in brain, Nature, 264, 568, 10.1038/264568a0 Dooley, 1993, Differential profile of the CCK-B receptor antagonist CI-988 and diazepam in the four-plate test, Psychopharmacology, 112, 452, 10.1007/BF02244893 Emson, 1982, Distribution of cholecystokinin in the human brain, J. Neurochem., 38, 1177, 10.1111/j.1471-4159.1982.tb05369.x Eysselein, 1986, Cholecystokinin gene structure, and molecular forms in tissue and blood, Gastroenterology, 24, 645 Fallon, 1985, The distribution and some connections of cholecystokinin neurons in the rat brain, Ann. NY Acad. Sci., 448, 121, 10.1111/j.1749-6632.1985.tb29912.x Fekete, 1981, Effect of cholecystokinin octopeptide sulphate ester on brain monoamines in the rat, Acta Physiol. Acad. Sci. Hung., 57, 37 Fendt, 1995, Cholecystokinin enhances the aucoustic starle response in rats, Neuroreport, 6, 2081, 10.1097/00001756-199510010-00030 Fuxe, 1980, Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection, Eur. J. Pharmacol., 67, 325, 10.1016/0014-2999(80)90521-X Geracioti, 1993, Cholecystokinin in human cerebrospinal fluid: concentrations, dynamics, molecular forms and relationship to fasting and feeding in health, depression and alcoholism, Brain Res., 629, 260, 10.1016/0006-8993(93)91329-Q Griez, 1987, CO2 vulnerability in panic disorder, Psychiatry Res., 20, 87, 10.1016/0165-1781(87)90001-1 Gulyás, 1991, Subpopulations of GABAergic neurons containing parvalbumin, calbindin D28k, and cholecystokinin in the rat hippocampus, J. Comp. Neurol., 312, 371, 10.1002/cne.903120305 Guttmacher, 1983, Pharmacologic models of anxiety, Comp. Psychiatry, 24, 312, 10.1016/0010-440X(83)90059-7 Haefely, 1994, Benzodiazepines, benzodiazepine receptors, and endogenous ligands, 573 Harper, 1943, Pancreoenzymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine, J. Physiol., 180, 77 Harro, 1991, Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat, Eur. J. Pharmacol., 193, 379, 10.1016/0014-2999(91)90156-K Harro, 1990, Anxiogenic-like action of caerulein, a CCK-8 receptor antagonist, in the mouse: influence of acute and subchronic diazepam treatment, Naunyn-Schmiedeberg's Arch. Pharmacol., 341, 62, 10.1007/BF00195059 Harro, 1990, Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain, Eur. J. Pharmacol., 180, 77, 10.1016/0014-2999(90)90594-V Harro, 1992, Changes in cholecystokinin receptor binding in rat brain after selective damage of the locus coeruleus projections by DSP-4 treatment, Arch. Pharmacol., 364, 425 Hays, 1980, Demonstration of a putative receptor site for cholecystokinin in rat brain, Neuropeptides, 1, 53, 10.1016/0143-4179(80)90009-8 Hendrie, 1993, The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice, Psychiatry Behav., 54, 689 Hendry, 1990, Neuropeptide-containing neurons of the cerebral cortex are also GABAergic, 81, 6526 Hill, 1990, Autoradiographic detection of cholecystokinin-A receptors in primate brain using125 Bolton Hunter CCK-8 and 3H-MK-329, J. Neurosci., 10, 1070, 10.1523/JNEUROSCI.10-04-01070.1990 Hoehn Saric, 1993, Effect of fluvoxamine on panic disorder, J. Clin. Psychopharmacol., 5, 321 Hökfelt, 1985, Distribution of cholecystokinin-like immunoreactivity in the nervous system: Co-existence with classical neurotransmitters and other neuropeptides, Ann. NY Acad. Sci., 488, 255, 10.1111/j.1749-6632.1985.tb29922.x Hökfelt, 1991, Distribution pattern of CCK and CCK mRNA in some neuronal and non-neuronal tissues, Neuropeptides, 19, 31, 10.1016/0143-4179(91)90081-S Horwell, 1991, Development of CCK-B antagonists, Neuropeptides, 19, 57, 10.1016/0143-4179(91)90083-U Hsiao, 1984, Cholecystokinin tetrapeptide proglumide and open-field behavior in rats, Life Sci., 34, 2165, 10.1016/0024-3205(84)90316-3 Hughes, 1990, Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity, 87, 6728 Innis, 1986, Distinct cholecystokinin receptors in brain and pancreas, 77, 6917 Itoh, 1988, Effect of cholecystokinin tetrapeptide amide on the metabolism of 5-hydroxytryptamine in de rat brain, Neuropharmacology, 27, 427, 10.1016/0028-3908(88)90152-9 Ivy, 1928, Hormone mechanism for gallbladder contraction and evacuation, Am. J. Physiol., 86, 599, 10.1152/ajplegacy.1928.86.3.599 Jeftinija, 1981, Cholecystokinin octapeptide excites dorsal horn neurons both in vivo and in vitro, Brain Res., 213, 231, 10.1016/0006-8993(81)91268-3 Kahn, 1991, m-Chlorophenylpiperazine as a probe of serotonin function, Biol. Psychiatry, 30, 1139, 10.1016/0006-3223(91)90184-N Kahn, 1988, Behavioral indications for serotonin receptor hypersensitivity in panic disorder, Psychiatry Res., 25, 101, 10.1016/0165-1781(88)90163-1 Keck, 1993, Valproate treatment of panic disorder and lactate-induced panic attacks, Biol. Psychiatry, 33, 542, 10.1016/0006-3223(93)90010-B Klein, 1991, Anxiogenic effects of m-CCP in patients with panic disorder: comparison to caffeine's anxiogenic effects, Biol. Psychiatry, 30, 973, 10.1016/0006-3223(91)90119-7 Kosaka, 1987, GABAergic neurons containing the Ca2+-binding protein parvalbumin in the rat hippocampus and dentate gyrus, Brain Res., 419, 119, 10.1016/0006-8993(87)90575-0 Koszycki, 1991, Dose ranging study of the effects of cholecystokinin in healthy volunteers, J. Psychiatr. Neurosci., 16, 91 Kramer, 1995, A placebo controlled trial of L-365,260, a CCKB antagonist, in panic disorder, Biol. Psychiatry, 37, 462, 10.1016/0006-3223(94)00190-E Kubota, 1989, Cholecystokinin antagonism by anthramycin, a benzodiazepine antibiotic, in the central nervous system in mice, Brain Res., 485, 62, 10.1016/0006-8993(89)90666-5 Lee, 1993, The human brain cholecystokinin-B/ gastrin receptor. Cloning and characterization, J. Biol. Chem., 268, 8164, 10.1016/S0021-9258(18)53076-3 Liebowitz, 1985, Imipramine in the treatment of panic disorder and its complications, Psychiatr. Clin. North Am., 8, 37, 10.1016/S0193-953X(18)30707-X Liebowitz, 1984, Lactate provocation of panic attacks. I. clinical and behavioral findings, Arch. Gen. Psychiatry, 41, 764, 10.1001/archpsyc.1984.01790190038004 Liebowitz, 1986, Possible mechanisms for lactate induction of panic, Am. J. Psychiatry, 143, 495, 10.1176/ajp.143.4.495 Lindefors, 1993, CCK peptides and mRNA in the human brain, Prog. Neurobiol., 40, 671, 10.1016/0301-0082(93)90010-P Lindefors, 1991, Distribution of cholecystokinin mRNA and peptides in the human brain, Neuroscience, 3, 813, 10.1016/0306-4522(91)90046-Q Lines, 1995, Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by cholecystokinin receptor subtype B antagonist L-365,260, Br. J. Pharmacol., 39, 235, 10.1111/j.1365-2125.1995.tb04442.x Lotti, 1987, In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist, J. Pharmacol. Exp. Ther., 241, 103 Lydiard, 1992, CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects, Am. J. Psychiatry, 149, 691, 10.1176/ajp.149.5.691 Mantyh, 1984, Evidence for cholecystokinin-like immunoreactive neurons in the rat medulla oblongata which project to the spinal cord, Brain Res., 291, 49, 10.1016/0006-8993(84)90649-8 McCann, 1995, Effects of pentagastrin in patients with social phobia and panic disorder and healthy volunteers Morin-Surun, 1983, Inhibitory effect of cholecystokinin octopeptide on neurons in the nucleus tractus solitarius, Brain Res., 265, 333, 10.1016/0006-8993(83)90352-9 Morley, 1990, Appetite regulation by gut peptides, Annu. Rev. Nutr., 10, 383, 10.1146/annurev.nu.10.070190.002123 Mutt, 1971, Hormonal polypeptides of the upper intestine, Biochem. J., 125, 57, 10.1042/bj1250057P Novak, 1988, Psychological well-being of primates in captivity, Am. J. Psychiatry, 43, 765 Ortiz, 1985, Effects of imipramine on lactate induced panic anxiety Palmour, 1992, The anxiogenic effects of CCK-4 in monkeys are reduced by CCK-B antagonists, benzodiazepines or adenosine A2 agonists, Eur. Neuropsychopharmacol., 2, 193, 10.1016/0924-977X(92)90058-G Patel, 1994, Measurement of central nervous system activity of systemically administered CCK-B receptor antagonists by ex vivo binding, Eur. J. Pharmacol., 253, 237, 10.1016/0014-2999(94)90197-X Payeur, 1993, Eur. Psychiatry, 25, 101 Paudice, 1991, Cholecystokinin release mediated by 5-HT, receptors in rat cerebral cortex and nucleus accumbens, Br. J. Pharmacol., 103, 1790, 10.1111/j.1476-5381.1991.tb09864.x Pearse, 1966, 5-Hydroxy-tryptophan uptake by dog thyroid C cells and its possible significance in polypeptide hormone production, Nature, 211, 598, 10.1038/211598a0 Pinnock, 1990, Cholecystokinin excites dorsal raphé neurones via a CCKA receptor, Br. J. Pharmacol., 100, 349P Pisegna, 1992, Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization, Biochem. Biophys. Res. Commun., 1, 296, 10.1016/0006-291X(92)91557-7 Pittaway, 1987, Cholecystokinin and pain, Pain Headache, 9, 213, 10.1159/000414635 Powell, 1991, Evaluation of the effect of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys, Neuropeptides, 19, 75, 10.1016/0143-4179(91)90085-W Praissman, 1983, Characterization of cholecystokinin binding sites in rat cerebral cortex using a 125-I-CCK-8 probe resistant to degradation, J. Neurochem., 40, 1406, 10.1111/j.1471-4159.1983.tb13583.x Raiteri, 1993, Inhibition by 5-HT3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats, Naunyn-Schmiedeberg's Arch. Pharmacol., 347, 111, 10.1007/BF00168781 Raiteri, 1993, Release of cholecystokinin in the central nervous system, Neurochem. Int., 22, 519, 10.1016/0197-0186(93)90025-Z Rasmussen, 1993, The CCK-B antagonist LY288513 blocks effects of the diazepam withdrawal on auditory startle, Neuroreport, 5, 154, 10.1097/00001756-199311180-00015 Rattray, 1993, Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain, Eur. J. Pharmacol., 245, 193, 10.1016/0922-4106(93)90129-W Rehfeld, 1978, Immunohistochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in central nervous system and small intestine of man and dog, J. Biol. Chem., 253, 4022, 10.1016/S0021-9258(17)34793-2 Rehfeld, 1986, Characterization of preprocholecystokinin products in the porcine cerebral cortex, J. Biol. Chem., 261, 5832, 10.1016/S0021-9258(17)38458-2 Rex, 1994, Effects of BOC-CCK-4 and L-365,260 on cortical 5-HT release in Guinea pigs on exposure to the elevated plus maze, Neuropharmacology, 33, 559, 10.1016/0028-3908(94)90087-6 Rex, 1994, Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety, Neurosci. Lett., 172, 139, 10.1016/0304-3940(94)90681-5 Rifkin, 1981, Blockade by imipramine or desipramine of panic induced by sodium lactate, Am. J. Psychiatry, 138, 676, 10.1176/ajp.138.5.676 Rose, 1989, Protection by serine peptidase inhibitors of endogenous choleystokinin released from brain slices, Neuroscience, 29, 583, 10.1016/0306-4522(89)90132-2 Rupniak, 1993, Failure of intravenous pentagastrin challenge to induce panic-like effects in Rhesus monkeys, Neuropeptides, 25, 115, 10.1016/0143-4179(93)90090-W Rybarczyk, 1990, Interaction of cholecystokinin and diazepam: effects on brain monoamines, Fundam. Clin. Pharmacol., 4, 245, 10.1111/j.1472-8206.1990.tb00491.x Sankaran, 1980, Binding of cholecystokinin to high affinity receptors on isolated pancreatic acini, J. Biol. Chem., 255, 18849, 10.1016/S0021-9258(19)85959-8 Schalling, 1990, Analysis of expression of cholecystokinin in dopamine cells in the ventral mesenchephalon of serval species and in humans with schizophrenia, 87, 8427 Singh, 1991, The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist, Br. J. Pharmacol., 104, 239, 10.1111/j.1476-5381.1991.tb12413.x Somogyi, 1984, Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin-immunoreactive material, J. Neurosci., 4, 2590, 10.1523/JNEUROSCI.04-10-02590.1984 Stengaard-Pedersen, 1984, Localization and opiate receptors binding of enkephalin, cholecystokinin, ACTH and β-endorphin in the rat central nervous system, Peptides, 23, 715 Tamminga, 1985, Cholecystokinin and neurotensin gradients in human CSF, Arch. Neurol., 42, 354, 10.1001/archneur.1985.04060040064013 Turkelson, 1990, A cholecystokininmetabolizing enzyme in the rat intestine, Peptides, 11, 213, 10.1016/0196-9781(90)90073-E Udhe, 1993, Pentagastrin model of anxiety in humans Van Megen, 1992, Single blind dose response study with cholecystokinin (CCK-4) in panic disorder patients, Clin. Neuropharmacol., 15, 532B, 10.1097/00002826-199202001-01038 Van Megen, 1994, Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients, Psychopharmacology, 114, 449, 10.1007/BF02249335 Van Megen, 1994, Effect of the cholecystokinin-B (CCK-B) receptor antagonist L365,260 on lactate induced panic attacks (PA), Psychopharmacology, 10, 3s Van Megen, 1994, Effect of the selective serotonin reuptake inhibitor (SRRI) Fluvoxamine on CCK-4 induced panic attacks, Psychopharmacology, 10, 270 Van Megen, 1994, On the significance of cholecystokinin receptors in panic disorder, Prog. Neuro-psychopharmacol., 18, 1235, 10.1016/0278-5846(94)90090-6 Van der Kooy, 1981, Separate populations of cholecystokinin and 5-hydroxytryptamine-containing neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections, Neurosci. Lett., 26, 25, 10.1016/0304-3940(81)90420-1 Van den Hout, 1984, Panic symptoms after inhalation of carbon dioxide, Br. J. Psychiatry, 144, 503, 10.1192/bjp.144.5.503 Vanderhaeghen, 1975, New peptide in the vertebrate CNS reacting with antigastrin antibodies, Nature, 257, 604, 10.1038/257604a0 Van Vliet, 1996 Vasar, 1993, Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the antiexploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze, Psychopharmacology, 110, 213, 10.1007/BF02246976 Vasar, 1994, Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze, Neuropharmacology, 33, 729, 10.1016/0028-3908(94)90112-0 Verhage, 1991, Characterization of the release of cholecystokinin-8 from isolated nerve terminals and comparison with exocytosis of classical transmitters, J. Neurochem., 56, 1394, 10.1111/j.1471-4159.1991.tb11437.x Wang, 1990, Cholecystokinin octapeptide antagonized opioid analgesia mediated by μ- and τ- but not δ-receptors in the spinal cord of the rat, Brain Res., 523, 5, 10.1016/0006-8993(90)91629-U Westenberg, 1994, The neuropharmacology of anxiety: a review on the role of serotonin, 405 Woodruff, 1991, Cholecystokinin antagonists, Annu. Rev. Pharmacol. Toxicol., 31, 469, 10.1146/annurev.pa.31.040191.002345 Woodruff, 1991, Functional role of brain CCK receptors, Neuropeptides, 19, 45, 10.1016/0143-4179(91)90082-T Yaksh, 1987, Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems, Brain Res., 406, 207, 10.1016/0006-8993(87)90784-0 Zandbergen, 1991, An analysis of panic symptoms during hypercarbia compared to hypocarbia in patients with panic attacks, J. Affect. Disord., 23, 131, 10.1016/0165-0327(91)90025-N